Opko Biologis
Israel· Est.
Platform biotech delivering long‑acting bio‑better protein therapeutics through CTP and reversible PEGylation technologies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $100M
AI Company Overview
Platform biotech delivering long‑acting bio‑better protein therapeutics through CTP and reversible PEGylation technologies.
EndocrinologyGrowth Disorders
Technology Platform
Proprietary CTP, reversible PEGylation, and stabilizer technologies that extend protein/peptide half‑life and improve formulation stability.
Opportunities
Licensing the CTP and reversible PEGylation platforms to larger pharma for diverse protein therapeutics; expanding into immunology and oncology indications.
Risk Factors
Reliance on a limited product portfolio for revenue; regulatory uncertainties for novel long‑acting formulations; competition from established long‑acting biologics developers.
Competitive Landscape
Competes with companies like Amgen, Pfizer, and biotech platforms offering half‑life extension technologies, but differentiates through its unique CTP peptide and reversible PEGylation approaches.